Springworks Therapeutics ( (SWTX) ) just unveiled an update.
On February 11, 2025, SpringWorks Therapeutics announced the FDA approval of GOMEKLI™ (mirdametinib), a treatment for neurofibromatosis type 1 with symptomatic plexiform neurofibromas, marking it as the first approved medicine for the condition. Based on Phase 2b trial results, GOMEKLI demonstrated significant tumor volume reduction and a manageable safety profile, offering a new therapeutic option for a condition affecting approximately 40,000 people in the US. This approval also granted SpringWorks a rare pediatric disease priority review voucher, further strengthening its market position in treating severe rare diseases.
More about Springworks Therapeutics
SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing treatments for severe rare diseases and cancer. The company recently received FDA approval for GOMEKLI™ (mirdametinib), a MEK inhibitor targeting neurofibromatosis type 1 with symptomatic plexiform neurofibromas.
YTD Price Performance: 52.80%
Average Trading Volume: 1,782,984
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $4.02B
For detailed information about SWTX stock, go to TipRanks’ Stock Analysis page.